<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954989</url>
  </required_header>
  <id_info>
    <org_study_id>BioEpo</org_study_id>
    <nct_id>NCT04954989</nct_id>
  </id_info>
  <brief_title>Biosimilarity Study of Subcutaneous Recombinant Human Erythropoietin in Healthy Volunteers</brief_title>
  <official_title>Phase I Open and Monocentric Clinical Trial With Pharmacokinetic and Pharmacodynamic Determination of Subcutaneous Recombinant Human Erythropoietin in Male Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Megalabs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Megalabs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label and monocentriC Phase I Clinical Trial, c to Determine the Pharmacokinetics and&#xD;
      Pharmacodynamics of Recombinant Human Erythropoietin for Subcutaneous Use in an Adult Male&#xD;
      Population&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of AUC0-t</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation Cmax</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Emax</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of ASEC0-t</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare profiles for T½ between the experimental drug and the comparator.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare profiles for Tmax between the experimental drug and the comparator.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Erythropoietin injectable in a single subcutaneous application.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietin Eprex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU</intervention_name>
    <description>Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously</description>
    <arm_group_label>Erythropoietin Eprex®</arm_group_label>
    <arm_group_label>Erythropoietin injectable in a single subcutaneous application.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Active comparator Erythropoietin Eprex® subcutaneous injection single dose of 4,000 IU</intervention_name>
    <description>Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of Eprex® should be administered subcutaneously</description>
    <arm_group_label>Erythropoietin Eprex®</arm_group_label>
    <arm_group_label>Erythropoietin injectable in a single subcutaneous application.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy eligible participants able to read, understand and sign the latest version of&#xD;
             the Informed Consent Form (FICF) approved by the Research Ethics Committee (CEP);&#xD;
&#xD;
          -  Male participants aged between 18 and 55 years;&#xD;
&#xD;
          -  Be characterized as a healthy research participant, based on medical history, general&#xD;
             physical examination and vital signs, laboratory tests and ECG not indicating any&#xD;
             evidence of disease;&#xD;
&#xD;
          -  Present BMI ≥ 18 and ≤ 29.9 Kg/m2;&#xD;
&#xD;
          -  Have a body weight of 60 - 100 kg;&#xD;
&#xD;
          -  Present a negative test for coronavirus.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Present one or more flu-like symptoms such as: fever (body temperature greater than or&#xD;
             equal to 37.8°C), cough, dyspnea, myalgia and fatigue, respiratory symptoms,&#xD;
             gastrointestinal symptoms (such as diarrhea) within 7 days prior to the hospital stay&#xD;
             (all periods);&#xD;
&#xD;
          -  Having had direct and significant contact, at the medical discretion, with people who&#xD;
             tested positive for a coronavirus test within 14 days prior to the hospital stay (all&#xD;
             periods);&#xD;
&#xD;
          -  Living in the same household as people who fall into the risk group of worse prognosis&#xD;
             for coronavirus infection, such as individuals over 60 years old, individuals with&#xD;
             respiratory problems, immunosuppressed or those with chronic diseases such as heart or&#xD;
             diabetes (all periods );&#xD;
&#xD;
          -  Any clinical condition or laboratory alteration that, at the investigator's&#xD;
             discretion, may compromise trial participation, ie:&#xD;
&#xD;
          -  Have an abnormal erythrocyte count (&lt;4.0 M/mm3 or &gt;5.4 M/mm3);&#xD;
&#xD;
          -  Have an abnormal reticulocyte count (&gt; 3.0%);&#xD;
&#xD;
          -  Have an abnormal platelet count (&lt; 135,000/μL or &gt; 550,000/μL);&#xD;
&#xD;
          -  Have an abnormal hemoglobin level (&lt; 13g/dL);&#xD;
&#xD;
          -  Have an abnormal level of hematocrit (&lt;40% or &gt;54%);&#xD;
&#xD;
          -  Have an abnormal level of ferritin (&lt; 100 ng/mL or &gt; 336.2 ng/mL);&#xD;
&#xD;
          -  Have an abnormal level of transferrin (&lt; 200 mg/dL or &gt; 360 mg/dL);&#xD;
&#xD;
          -  Have an abnormal level of transferrin saturation (&lt;20%)&#xD;
&#xD;
          -  Have abnormal levels of vitamin B12 (&lt; 130 pg/mL or &gt;868 pg/mL);&#xD;
&#xD;
          -  Present evidence of cardiovascular disorders, particularly arterial hypertension&#xD;
             (supine blood pressure &gt; 145 / 90mmHg at baseline);&#xD;
&#xD;
          -  History of venous thrombosis;&#xD;
&#xD;
          -  Participants diagnosed with iron deficiency anemia or clinical history of autoimmune&#xD;
             or hereditary anemia;&#xD;
&#xD;
          -  Clinical history of chronic or acute hemorrhages in the 30 days preceding the start of&#xD;
             the trial;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Pedrazzoli Junior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade Integrada de Farmacologia e Gastroenterologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcos Giusti, MD</last_name>
    <phone>+598926838000</phone>
    <email>mgiusti@megalabs.global</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Rodríguez, MD</last_name>
    <email>vrodriguez@megalabs.global</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reticulocytes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

